COMPASS Pathways plc CMPS

Updated: 9 Aug 2026

NASDAQ | Biotech | Psychotropics and psychedelic therapy

No signal published yet

We already track COMPASS Pathways and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow COMPASS Pathways free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Psychotropics and psychedelic therapy
We're already tracking COMPASS Pathways plc — here are the latest events we've registered

Recent News

  • On August 5, 2026, COMPASS Pathways reported its second-quarter 2026 financial results, highlighting a cash position of $433.3 million. The company confirmed that its rolling New Drug Application submission to the FDA for COMP360 in treatment-resistant depression remains on track for completion in the fourth quarter of 2026.

What Firelda Watch includes for COMPASS Pathways plc

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of COMPASS Pathways plc will be delivered in the same format.

Want to follow COMPASS Pathways plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow COMPASS Pathways free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

COMPASS Pathways plc CMPS
COMPASS Pathways — follow and we'll monitor it
Follow COMPASS Pathways free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.